Rivastigmine transdermal - Luye Pharma

Drug Profile

Rivastigmine transdermal - Luye Pharma

Alternative Names: Rivastigmine MD

Latest Information Update: 22 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Acino
  • Developer Luye Pharma Group
  • Class Antidementias; Phenylcarbamates; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Butyrylcholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 05 Apr 2017 Chemical structure information added
  • 06 Mar 2017 Luye Pharma plans a phase I trial for Alzheimer's disease in Germany
  • 06 Mar 2017 Preclinical trials in Alzheimer's disease in China prior to March 2017 (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top